Navigation Links
Eisai and Bial Announce Partnership Agreement for the European Commercialisation of the Novel Once Daily Anti-Epileptic Zebinix(R)
Date:2/19/2009

LONDON, February 19 /PRNewswire-FirstCall/ --

- Eisai Set to Become an Emerging Leader in the Treatment of Epilepsy

Eisai Europe Ltd (London; Chairman & CEO Yutaka Tsuchiya), the European subsidiary of Eisai Co., Ltd. (Tokyo, President & CEO: Haruo Naito), and Bial-Portela & CA, S.A., (S. Mamede do Coronado, Portugal, CEO Dr Luis Portela) today announced the signing of a licence and co-promotion agreement in which Eisai receives a sole license to market, promote and distribute the novel once daily anti-epileptic Zebinix(R) (eslicarbazepine acetate), within Europe(1).

Under the terms of the agreement, Bial will receive EUR95million consisting of an upfront payment plus milestone payments for further epilepsy approvals within Europe. Bial will maintain ongoing development and production rights and the option to co-promote with Eisai throughout Europe and will supply finished product to Eisai.

Zebinix(R), subject to approval by the European Medicines Agency (EMEA), will initially be indicated for the adjunctive treatment of partial-onset seizures, with or without secondary generalisation, in patients 18 years and older with epilepsy. Zebinix(R) was submitted to the EMEA by Bial in March 2008 and approval is anticipated in Q2 2009.

The safety and efficacy of Zebinix(R) has been shown in three phase III double-blind, randomised placebo-controlled trials in 1,049 patients with partial onset seizures. Additionally, these subjects were followed up long term in an open label extension. In these studies, Zebinix(R) demonstrated significant sustained improvements in seizure frequency, reduced depressive symptoms, and significantly improved scores in health related quality of life.

"It is as important to consider the implications on the quality of a patient's day-to-day life, as well as effective seizure control, when making the therapeutic evaluation
'/>"/>

SOURCE Eisai Europe Ltd and Bial
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. Eisai Corporation of North America Announces Appointment of Vice President of U.S. Corporate Communications
2. Eisai Inc. and the Alzheimers Association Introduce the C.A.R.E. Pharmacy Award and Call for Nominations
3. Eisai Renews Its Commitment to Responsible Healthcare Community Interactions in Accordance with the Revised PhRMA Marketing Code
4. Eisai Inc. Supports Acting Surgeon Generals Call to Action to Prevent Deep Vein Thrombosis and Pulmonary Embolism
5. Biologic Drugs, Particularly Centocor/Janssen-Cilags Stelara and Abbott/Eisais Humira, will Drive the Psoriasis Drug Market to $5 Billion by 2017
6. Eisai Will Initiate First Head-to-Head Study Comparing Dacogen(R) (decitabine for injection) and Vidaza(R) (azacitidine) in Patients with Myelodysplastic Syndromes
7. Eisai Inc. and the North American Thrombosis Forum (NATF)* Introduce the DVTeamCare(TM) Hospital Award and Call for Nominations
8. HHS Announces $75 Million in Supplemental Funding to States for Pandemic Flu Preparedness
9. CRC Health Group Announces Acquisition of Bayside Marin Recovery Center, San Rafael
10. UHW Announces: Antelope Valley Hospital Caregivers and Board Vote to Ratify First Union Contract With SEIU UHW-West
11. HEI, Inc. Announces Sale of RFID Division Assets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/26/2014)... (PRWEB) December 26, 2014 DW-InductionHeating.com (DaWei ... in designing, researching and developing, producing and marketing of ... of the business announces their new series of ... manager of the company, induction brazing refers ... a special filler material and heat. The manager says ...
(Date:12/25/2014)... The report “Nintedanib (Colorectal Cancer) – ... the current treatment landscape, unmet needs, current pipeline ... Stivarga is a drug which is used in ... Ingelheim is developing nintedanib (BIBF-1120), an orally available ... in the US, Europe, and Japan. The drug ...
(Date:12/25/2014)... Recently, Dylan Queen, a famous online company supplying ... of discounted prom dresses, most of which are priced ... the company, the promotion is valid until Jan. 22, ... the UK market. , The prom dresses in this ... styles: A-line strapless, empire strapless chiffon, one shoulder, floor-length, ...
(Date:12/25/2014)... When head lice hits a home or school, parents and ... of it while keeping it from taking over the house ... solution right in their neighborhood: Lice Troopers . Expanding ... spectrum head lice screening and treatment services to families and ... Brickell, Coconut Grove, Kendall, Pinecrest and South Miami. , The ...
(Date:12/25/2014)... early stage breast cancer patients who undergo chemotherapy and/or ... eventually develop leukemia as a result of their treatment, ... a review of more than 20,000 breast cancer cases ... the risk for developing treatment-related leukemia, though low, is ... frequency of bone marrow cancers such as leukemia is ...
Breaking Medicine News(10 mins):Health News:Induction Brazing Equipment Series From DaWei Induction Heating Co., A Reliable Supplier Of Induction Heating Equipment 2Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 4Health News:Dylan Queen: Cheap Prom Dresses for the UK Market 2Health News:Coral Gables Florida Gets Ready to Be Lice-Free with Lice Troopers 2Health News:Breast Cancer Chemo Tied to Small But Significant Leukemia Risk 2Health News:Breast Cancer Chemo Tied to Small But Significant Leukemia Risk 3
... advisory committee to the U.S. Food and Drug Administration recommended ... used without a prescription. The FDA does not have to ... does. There is no deadline for making a decision. // ... the ability to do both good and harm. Claritin, Allegra ...
... Hypertensive drugs in general have a common side effect- ... plagues people on a widely-used blood pressure medication.// ... treat high blood pressure, heart failure and other cardiac ... inhibitors are troubled by a cough. The side effect ...
... contains polyphenols in the form of flavonoids and its ... properties. Polyphenols protect the cells from damaging// physiological process ... Oxidation produces free radicals these are unstable ... increased amount of them can damage cells resulting in ...
... supplements of a fatty acid found in fish oil halves ... research has found that eating oily fish such as tuna ... caused by a particular type of irregular heartbeat. This study ... a therapy without side effects for heart patients. ...
... to a new study shows that women with ... 'good' cholesterol when they take oestrogen.// Previous research suggests ... heart disease. Now doctors at Forest University have discovered ... profile responds to HRT. ,An analysis of over ...
... An Australian psychiatrist has discovered that treating patients with ... Although antipsychotic drugs like risperidone have been shown to ... researchers have suspected for some time that oestrogen can ... version of the disease than men and it usually ...
Cached Medicine News:
(Date:12/24/2014)...  Novastem, a leader in regenerative medicine, announces ... study for ischemic stroke at Clinica Santa Clarita. ... account for 87 percent of all stroke cases. ... study, entitled "Internal Research Protocol in Combination Therapy ... and Intrathecal Administration of Neural Stem Cells in ...
(Date:12/24/2014)... China, Dec. 24, 2014 /PRNewswire/  -- Tianyin Pharmaceutical ... pharmaceutical company that specializes in the patented biopharmaceutical, ... active pharmaceutical ingredients (API) released unaudited preliminary financial ... 2015. Fiscal Year 2015 Ended September ... $9.7 million compared with $14.7 million in 1Q14 ...
(Date:12/24/2014)... -- The International Trade Commission (ITC) issued its final decision in ... a notice issued on December 23, the ITC ruled in ... humidifier was invalid. BMC President, James Xu ... excited with the ITC,s decision in this case. This victory ... the very beginning on the key patents in the case. ...
Breaking Medicine Technology:Novastem Treats First Patient Using Stemedica's Mesenchymal and Neural Stem Cell Combination Therapy for Ischemic Stroke 2Novastem Treats First Patient Using Stemedica's Mesenchymal and Neural Stem Cell Combination Therapy for Ischemic Stroke 3Novastem Treats First Patient Using Stemedica's Mesenchymal and Neural Stem Cell Combination Therapy for Ischemic Stroke 4TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 2TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 3TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 4TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 5TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 6TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 7TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 8TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 9TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 10TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 11TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 12ITC Final Decision Goes Against ResMed (RMD) Monumental Win for 3B/BMC 2
... 8, 2007--The World Health Organization,has released new ... rising in,Pakistan. , So is this another ... pharmaceutical industry is denying important vaccines to,poor ... to London’s Guardian,newspaper, “parents of 24,000 children ...
... Outlines Development Plans - , ,OTTAWA, Canada – ... company specializing in developing,advanced products related to High ... results of,the Phase I/II Clinical Trial of its ... treatment of dyslipidemia and heart,disease. , ,Results showed, ...
Cached Medicine Technology:Why Is Polio Spreading in Pakistan? 2Liponex Inc. Reports Phase I/II Clinical Trial Data for CRD5 2Liponex Inc. Reports Phase I/II Clinical Trial Data for CRD5 3
... elitewas designed to improve patient compliance. Its ... sample collection options make this fecal occult ... and complete. Diet guidelines are explained in ... which foods and drugs are okay and ...
Inquire...
... The FSH Menopause Predictor Test ... for the detection of Follicle Stimulating ... confirmation of body hormone changes related ... changes of menopause. The FHS ...
... pylori Rapid Test Strip and Device are ... of antibodies to Helicobacter pylori (H. pylori) ... aid in the diagnosis of H. pylori ... and older. They are intended for health ...
Medicine Products: